This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342
Giantonio B et al. (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol 23 (Suppl): aS2
de Gramont A et al. (2005) Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 (Suppl 3): 46–56
Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65
Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685–693
Cassidy J et al. (2006) First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) [abstract]. Ann Oncol 17 (Suppl 9): LBA 3
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
HI Hurwitz has declared associations with the following companies: Genentech, Roche. See the article online for full details of the relationship. HE Uronis declared she has no competing interests.
Rights and permissions
About this article
Cite this article
Uronis, H., Hurwitz, H. Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?. Nat Rev Clin Oncol 4, 214–215 (2007). https://doi.org/10.1038/ncponc0748
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0748
This article is cited by
-
A review on various targeted anticancer therapies
Targeted Oncology (2012)